Medicus Pharma (MDCX) Short term Debt (2025 - 2026)

Medicus Pharma's (MDCX) quarterly Short term Debt came in at $5.2 million in Q4 2025, down 22.7% on a QoQ basis from $6.8 million in Q3 2025.

Medicus Pharma (MDCX) Short term Debt (2025 - 2026) Analysis & Trends

Medicus Pharma (MDCX) has 1 years of Short term Debt data on file, last reported at $5.2 million in Q4 2025.

Quarterly Short term Debt changed N/A year-over-year to $5.2 million in Q4 2025, while the trailing twelve-month figure through Dec 2025 was $5.2 million (changed N/A YoY) and the FY2025 annual result came in at $5.2 million, changed N/A from the prior year.
Short term Debt fell to $5.2 million in Q4 2025, from $6.8 million in the prior quarter.
In the past five years, Short term Debt ranged from a high of $6.8 million in Q3 2025 to a low of $4.7 million in Q2 2025.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Johnson & Johnson	652.20 Bn	631.44 Bn	17.26 Bn
2	AbbVie	469.51 Bn	462.94 Bn	12.70 Bn
3	Merck	376.81 Bn	369.67 Bn	12.21 Bn
4	Novartis Ag	303.04 Bn	295.35 Bn	11.24 Bn
5	Astrazeneca	257.61 Bn	252.71 Bn	12.86 Bn
6	Amgen	237.37 Bn	223.38 Bn	7.24 Bn
7	Gilead Sciences	181.73 Bn	178.55 Bn	6.22 Bn
8	Pfizer	159.66 Bn	147.96 Bn	10.94 Bn
9	Gsk	106.24 Bn	102.07 Bn	8.24 Bn
10	Medicus Pharma	14.88 Mn	-298,205.43	-

Download Data